192 related articles for article (PubMed ID: 23437240)
1. PAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from meta-analysis.
Wang S; Cao Q; Wang X; Li B; Tang M; Yuan W; Fang J; Qian J; Qin C; Zhang W
PLoS One; 2013; 8(2):e56797. PubMed ID: 23437240
[TBL] [Abstract][Full Text] [Related]
2. Association between plasminogen activator inhibitor-1 -675 4G/5G polymorphism and sepsis: a meta-analysis.
Li L; Nie W; Zhou H; Yuan W; Li W; Huang W
PLoS One; 2013; 8(1):e54883. PubMed ID: 23382992
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator inhibitor-1 4G/5G gene polymorphism and coronary artery disease in the Chinese Han population: a meta-analysis.
Li YY
PLoS One; 2012; 7(4):e33511. PubMed ID: 22496752
[TBL] [Abstract][Full Text] [Related]
4. Association Between Plasminogen Activator Inhibitor-1 Genetic Polymorphisms and Stroke Susceptibility.
Hu X; Zan X; Xie Z; Li Y; Lin S; Li H; You C
Mol Neurobiol; 2017 Jan; 54(1):328-341. PubMed ID: 26742513
[TBL] [Abstract][Full Text] [Related]
5. Association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and risk of Alzheimer's disease, metabolic syndrome, and female infertility: A meta-analysis.
Zhang X; Gao B; Xu B
Medicine (Baltimore); 2020 Dec; 99(50):e23660. PubMed ID: 33327353
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of the association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss.
Li X; Liu Y; Zhang R; Tan J; Chen L; Liu Y
Med Sci Monit; 2015 Apr; 21():1051-6. PubMed ID: 25862335
[TBL] [Abstract][Full Text] [Related]
7. Association between the 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene and sudden sensorineural hearing loss in Caucasian population: a meta-analysis.
Wei Z; Chang K; Fan C
Eur Arch Otorhinolaryngol; 2021 Jul; 278(7):2203-2208. PubMed ID: 32901365
[TBL] [Abstract][Full Text] [Related]
8. Association between PAI-1 4G/5G polymorphism and diabetic nephropathy: a meta-analysis in the Chinese population.
Gao WF; Guo YB; Bai Y; Ding XY; Yan YJ; Wu ZQ
Int Urol Nephrol; 2016 Sep; 48(9):1483-9. PubMed ID: 27272255
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis.
Zhang T; Pang C; Li N; Zhou E; Zhao K
BMC Med; 2013 Jan; 11():1. PubMed ID: 23281898
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome: a meta-analysis.
Lee YH; Song GG
Eur J Obstet Gynecol Reprod Biol; 2014 Apr; 175():8-14. PubMed ID: 24439532
[TBL] [Abstract][Full Text] [Related]
12. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis.
Wang J; Wang C; Chen N; Shu C; Guo X; He Y; Zhou Y
Thromb Res; 2014 Dec; 134(6):1241-8. PubMed ID: 25450536
[TBL] [Abstract][Full Text] [Related]
13. PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis.
Xu X; Xie Y; Lin Y; Xu X; Zhu Y; Mao Y; Hu Z; Wu J; Chen H; Zheng X; Qin J; Xie L
Exp Ther Med; 2012 Dec; 4(6):1127-1133. PubMed ID: 23226787
[TBL] [Abstract][Full Text] [Related]
14. PAI-1 -675 4G/5G polymorphism in association with diabetes and diabetic complications susceptibility: a meta-analysis study.
Xu K; Liu X; Yang F; Cui D; Shi Y; Shen C; Tang W; Yang T
PLoS One; 2013; 8(11):e79150. PubMed ID: 24223897
[TBL] [Abstract][Full Text] [Related]
15. The -675 4G/5G polymorphism in plasminogen activator inhibitor-1 gene is associated with risk of asthma: a meta-analysis.
Nie W; Li B; Xiu QY
PLoS One; 2012; 7(3):e34385. PubMed ID: 22479620
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen Activator Inhibitor-1 Polymorphism Confers a Genetic Contribution to the Risk of Recurrent Spontaneous Abortion: An Updated Meta-Analysis.
Huang Z; Tang W; Liang Z; Chen Q; Li M; Li Y; Lao S; Pan H; Huang L; Huang M; Hu X; Zhao J
Reprod Sci; 2017 Nov; 24(11):1551-1560. PubMed ID: 28395596
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis.
Lee JH; Kim Y; Choi JW; Kim YS
Arch Med Res; 2013 Jan; 44(1):39-45. PubMed ID: 23291383
[TBL] [Abstract][Full Text] [Related]
18. Association between plasminogen activator inhibitor‑1 (PAI-1) 4G/5G polymorphism and circulating PAI-1 level in systemic lupus erythematosus and rheumatoid arthritis : A meta-analysis.
Bae SC; Lee YH
Z Rheumatol; 2020 Apr; 79(3):312-318. PubMed ID: 31428858
[TBL] [Abstract][Full Text] [Related]
19. PAI-1 Gene Polymorphism Was Associated with an Increased Risk of Allergic Diseases: Evidence from a Meta-Analysis of 14 Case-Control Studies.
Zheng L; Li X; Song Q; Hou C; Chen X; Li B
Int Arch Allergy Immunol; 2019; 180(4):255-263. PubMed ID: 31574527
[TBL] [Abstract][Full Text] [Related]
20. The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer.
Yıldırım ME; Karakuş S; Kurtulgan HK; Kılıçgün H; Erşan S; Bakır S
Biochem Genet; 2017 Aug; 55(4):314-321. PubMed ID: 28303356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
